{
    "paper_id": "PMC7211719",
    "metadata": {
        "title": "Five variable that rule your life \u2013 Home mortgage and biostatistical power",
        "authors": [
            {
                "first": "Gary",
                "middle": [
                    "D."
                ],
                "last": "Novack",
                "suffix": "",
                "email": null,
                "affiliation": {}
            }
        ]
    },
    "body_text": [
        {
            "text": "\n\u2022Acucela continues development of emixustat for the treatment of retinal degeneration based upon a recent publication9 (December 2019), and press release regarding continued enrollment in a Phase 3 trial in patients with Stargardt disease (February 2020).\u2022Aerie announced that the European Medicines Agency (EMA) has accepted for review the marketing authorization application (MAA) for Roclanda (netarsudil and latanoprost ophthalmic solution, currently marketed as Rocklatan in the United States (January 2020).\u2022Aerpio announced results from the fifth cohort of subjects from a Phase 1b trial of a topical ocular formulation of AKB-9778 in patients with ocular hypertension (OHT) or primary open angle glaucoma (POAG, January 2020).\u2022Alcon received U.S. FDA approval for switching Pataday\u00ae (olopatadine) from prescription to over-the-counter (February 2020).\u2022Aldeyra started enrollment in its Phase 3 INVIGORATE Trial of topical ocular reproxalap in patients with allergic conjunctivitis. The firm also started enrollment in a Phase trial of ADX-2191 (intravitreal methotrexate) for the prevention of recurrent retinal detachment due to proliferative vitreoretinopathy (January 2020).\u2022Allysta Pharmaceuticals started enrollment in a phase 1/2a trial of ALY688, a novel peptide agonist that binds to and activates adiponectin receptors, in patients with dry eye disease (January 2020).\u2022Dutch Ophthalmic Research Centre (DORC) received FDA approval for its Brilliant Blue for the visualization of internal limiting membranes (December 2019).\u2022EyeGate Pharma released results from a dry eye pilot study with its Ocular Bandage Gel (March 2020).\u2022Genentech and Roche started enrolled in a phase 3 trial of its Port Delivery System with ranibizumab (PDS) in people with diabetic macular edema (DME, January 2020).\u2022Graybug completed enrollment in its Phase 2b trial of its GB-10 intravitreal drug delivery system of sunitinib for the treatment of wet AMD.\u2022HanAll Biopharma and Daewoong Pharmaceutical announced topline results from the first US Phase 3 study of HL036 for treatment of dry eye (VELOS-2 study, January 2020).\u2022Horizon received FDA approval for its Tepezza\u2122 (teprotumumab) as a treatment for thyroid eye disease (January 2020).\u2022Iveric announced results for its Zimura (avacincaptad pegol), a novel C5 inhibitor, in a phase 2b trial for the treatment of patients with geographic atrophy (GA) secondary to AMD. They also announced the design for a second trial (January 2020).\u2022Kala announced results from its Phase 3 STRIDE study evaluating KPI-121 0.25% (EYSUVIS\u2122, loteprednol etabonate ophthalmic suspension) for the treatment of dry eye disease (March 2020).\u2022Leo Lens Pharma announced a notice of allowance from the U.S. Patent and Trademark Office for its proprietary MediPrint\u2122 process for contact lens delivery of drugs (February 2020).\u2022Novartis received approval from the European Commission for its Beovu\u00ae (brolucizumab) for the treatment of wet age-related macular degeneration (AMD, (February 2020).\u2022Ocular Therapeutix presented results from its Phase 1, multi-center, open-label, dose escalation clinical trial being conducted in Australia is intended to evaluate OTX-TKI, a tyrosine kinase inhibitor implant) for the treatment of wet AMD (March 2020).\u2022Oculis reported results from a phase 2 study of its OCS-01 (a novel eye drop formulation of dexamethasone) in patients with diabetic macular edema (DME, February 2020).\u2022Ocuphire entered into an agreement with Apexian Pharmaceuticals, Inc., granting Ocuphire an exclusive worldwide sublicense to Apexian\u2019s Ref-1 Inhibitor program, including its lead drug candidate APX3330, for all ophthalmic and diabetic indications (January 2020).\u2022Oyster Point Pharma announced the top-line results from its Phase 2 MYSTIC study of OC-01 (in Dry Eye Disease (January 2020).10\n\u2022ProQR received rare pediatric disease designation for its QR-421a RNA-based oligonucleotide for the treatment of Usher Syndrome (January 2020). The firm also announced results from its Phase 1/2 study (March 2020).\u2022Santen cleared a regulatory hurdle to make its Verkazia\u00ae (cyclosporine) available for patients with severe vernal keratoconjunctivitis in Quebec (January 2020).\u2022Tetra Bio-Pharma received orphan drug designation from the U.S. FDA for its cannabinoid PPP003 to prevent proliferative vitreoretinopathy (April 2020).\n",
            "cite_spans": [
                {
                    "start": 118,
                    "end": 119,
                    "mention": "9",
                    "ref_id": "BIBREF20"
                },
                {
                    "start": 3827,
                    "end": 3829,
                    "mention": "10",
                    "ref_id": "BIBREF1"
                }
            ],
            "section": "Government and public health news",
            "ref_spans": []
        },
        {
            "text": "\n\u2022Adverum dosed the first patient in cohort 4 of phase 1 OPTIC trial of intravitreal ADVM-022, a vector capsid for aflibercept (April 2020).\u2022Applied Genetic Technologies Corporation reported interim six-month data from its ongoing Phase 1/2 clinical program in X-linked retinitis pigmentosa (XLRP, January 2020).\u2022Editas announced treatment of a patient with intraocular CRISPR gene editing to treat a patient with a retinal degeneration (March 2020).\u2022Lineage Cell Therapeutics provided an update on its ongoing Phase 3 study for the treatment of dry age-related macular degeneration of OpRegen, a retinal pigment epithelium transplant therapy delivered subretinally using a delivery system from Gyroscope Therapeutics (February 2020).\u2022Regenxbio announced results from an ongoing Phase 1/2a trial of its RGX-314 gene therapy for wet AMD (April 2020).\n",
            "cite_spans": [],
            "section": "Gene therapy",
            "ref_spans": []
        },
        {
            "text": "\n\u2022Alexion completed its acquisition of Achillion (January 2020).\u2022Santen Pharmaceutical and the Alphabet subsidiary, Verily announced the establishment of a joint venture focused on applying microelectronics and scalable digital technologies to ophthalmology (February 2020).\u2022A growing number of states are proposing laws to ban cosmetics the safety of which is testing on animals prior to marketing. Animal-tested cosmetics already are banned in Europe, India and elsewhere (January 2020).\u2022The practice of dispensing 90-days of medication, efficient for healthcare delivery, was questioned for patients with depressive disorders, as it may provide them an easily available method to commit suicide.11\n\u2022There is a growing realization that sponsors of clinical trials are not complying with the law regarding posting of results on clinicaltrials.gov. The apparent non-compliers include academic, government and industry-sponsored studies (January 2020).12\n\u2022A number of drugs are projected to lose exclusivity in the U.S. in 2020, the top ten of which had $8 billion in 2019 U.S. sales (March 2020).\u2022Roche is supplying its arthritis drug Actemra\u00ae (tocliziumab) to doctors treating patients with COVID-19 infections. Note that this use is investigational (March 2020).\u2022The University of California and the Public Library of Science (PLOS) announced a two-year agreement that will make it easier and more affordable for UC researchers to publish in the nonprofit open access publisher\u2019s suite of journals (February 2020).\u2022In this review period, the FDA:\noReleased a guidance for Human Gene Therapy for Retinal Disorders (January 2020).\noConducted of a study on brand names of drugs with respect to how they influence consumers\u2019 and healthcare providers\u2019 perceptions, and may overstate efficacy (January 2020).13\n\noPublished a cumulative dataset on approved new molecular entities (drug and biologic) approvals from 1985-2019 (March 2019).\n\u2022The COVID-19 pandemic has had a major impact on government regulation and ophthalmic practice and research. Selected items of interest include:\noThe ophthalmic and medical community is recognizing the role played by Dr. Li Wenliang, ophthalmologist, of Wuhan, China, for his early work in identifying the clinical signs and symptoms of the COVID-19 virus (March 2020).14\n\noA group of leaders in the retinal ophthalmic pharmaceutical industry issued a joint statement on prioritizing patient safety for patients in trials of therapies for retinal diseases at this time of the COVID pandemic, including minimizing study visits and enrollment of new patients (Genentech, Boehringer Ingelheim, Kodiak Sciences, Apellis Pharmaceuticals, Graybug Vision, Bayer, Adverum, Novartis and REGENXBIO; March 2020).\noThe FDA issued a statement regarding the pragmatic challenges of conducting clinical trials, especially considering the American Academy of Ophthalmology recommendation to limit patient interaction to urgent care (March 2020).\noThe U.S. Federal leadership discussed using \u201cre-purposing\u201d of molecules approved for other indications, and the rubric \u201cit couldn\u2019t hurt\u201d. These development pathways and concerns have been addressed previously.15, 16, 17\n\noA controlled trial of lopinivar-ritonavir in adults with severe COVID-19 showed no benefit.18 Chloroquine was reported effective in an open-label trial in the treatment of COVID-19,19 however, the International Society of Antimicrobial Chemotherapy subsequently stated that the article \u201cdoes not meet the [society\u2019s] expected standard, especially relating to the lack of better explanations of the inclusion criteria and the triage of patients to ensure patient safety.\u201d20\n\noContinuing to facilitate development of treatments, the FDA including a statement (as of 19 March 2020) that \u201cWhile there are no FDA-approved therapeutics or drugs to treat, cure or prevent COVID-19, there are several FDA-approved treatments that may help ease the symptoms from a supportive care perspective\u201d\noFDA expressed concern regarding therapeutic products that are derived from human cells, tissues or cellular or tissue-based products (HCT/Ps) related to the ongoing COVID-19 (corona virus) outbreak (February 2020).\noFDA postponed all foreign inspections due to the COVID-19 pandemic (March 2020). In a related article, this has challenged the U.S. reliance on foreign drug manufacture, estimated as 40% of finished medications and 80% of active pharmaceutical ingredients (April 2020).21\n\noCepheid\u2019s point-of-care diagnostic for COVID-19 was authorized for use by the U.S. FDA (March 2020).\noFDA is expediting clinical trials for diagnosis and treatment, albeit with continued concern for patient safety (March 2020).\noFDA declared a public health service emergency authorizing emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19.\noFA expanded the availability and capability of non-invasive remote monitoring devices to facilitate patient monitoring (March 2020).\noFDA temporarily allowed compounding of selected medications (April 2020).\noFDA converted planned in-person meetings to teleconferences (April 2020)\noFDA an emergency use authorization for the investigational antiviral drug remdesivir for the treatment of suspected or laboratory-confirmed COVID-19 in adults and children hospitalized with severe disease (May 2020).\n\n",
            "cite_spans": [
                {
                    "start": 698,
                    "end": 700,
                    "mention": "11",
                    "ref_id": "BIBREF2"
                },
                {
                    "start": 951,
                    "end": 953,
                    "mention": "12",
                    "ref_id": "BIBREF3"
                },
                {
                    "start": 1804,
                    "end": 1806,
                    "mention": "13",
                    "ref_id": "BIBREF4"
                },
                {
                    "start": 2303,
                    "end": 2305,
                    "mention": "14",
                    "ref_id": "BIBREF5"
                },
                {
                    "start": 3175,
                    "end": 3177,
                    "mention": "15",
                    "ref_id": "BIBREF6"
                },
                {
                    "start": 3179,
                    "end": 3181,
                    "mention": "16",
                    "ref_id": "BIBREF7"
                },
                {
                    "start": 3183,
                    "end": 3185,
                    "mention": "17",
                    "ref_id": "BIBREF8"
                },
                {
                    "start": 3279,
                    "end": 3281,
                    "mention": "18",
                    "ref_id": "BIBREF9"
                },
                {
                    "start": 3658,
                    "end": 3660,
                    "mention": "20",
                    "ref_id": "BIBREF12"
                },
                {
                    "start": 4459,
                    "end": 4461,
                    "mention": "21",
                    "ref_id": "BIBREF13"
                }
            ],
            "section": "Regulatory, Government, and Pharmaceutical Industry",
            "ref_spans": []
        },
        {
            "text": "Gary D. Novack PhD consults with numerous pharmaceutical firms.",
            "cite_spans": [],
            "section": "Disclosure",
            "ref_spans": []
        },
        {
            "text": "\n19.",
            "cite_spans": [
                {
                    "start": 1,
                    "end": 3,
                    "mention": "19",
                    "ref_id": "BIBREF10"
                }
            ],
            "section": "Uncited References",
            "ref_spans": []
        }
    ],
    "ref_entries": {
        "TABREF0": {
            "text": "Table 1: Example of sample size calculations for dry eye therapeutic trials.\n",
            "type": "table"
        },
        "FIGREF0": {
            "text": "Figure 1: Example of monthly mortgage payment (principal and interest) as a function of down payment Down payment is shown using the left hand axis, and monthly mortgage payment is shown using the right hand axis. Assuming $500,000 house, 4% interest rate and 30 year loan. Does not include real estate taxes, mortgage insurance, closing costs, or home insurance.",
            "type": "figure"
        }
    },
    "back_matter": [],
    "bib_entries": {
        "BIBREF0": {
            "title": "Ophthalmic Beta-Blockers since Timolol",
            "authors": [
                {
                    "first": "G.D.",
                    "middle": [],
                    "last": "Novack",
                    "suffix": ""
                }
            ],
            "year": 1987,
            "venue": "Survey of Ophthalmology",
            "volume": "31",
            "issn": "5",
            "pages": "307-327",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF1": {
            "title": "Pipeline: Product Exclusivity Granted by the U.S. Food and Drug Administration",
            "authors": [
                {
                    "first": "G.D.",
                    "middle": [],
                    "last": "Novack",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "Ocul Surf",
            "volume": "14",
            "issn": "1",
            "pages": "74-76",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF2": {
            "title": "",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF3": {
            "title": "Transparency on trial",
            "authors": [
                {
                    "first": "C.",
                    "middle": [],
                    "last": "Piller",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Science",
            "volume": "367",
            "issn": "6475",
            "pages": "240-243",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF4": {
            "title": "Agency Information Collection Activities; Proposed Collection; Comment Request; Empirical Study of Promotional Implications of Proprietary Prescription Drug Names",
            "authors": [
                {
                    "first": "",
                    "middle": [],
                    "last": "Anonymous",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Fed Reg",
            "volume": "85",
            "issn": "13",
            "pages": "3392-3394",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF5": {
            "title": "",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF6": {
            "title": "Pipeline: The \"In-between\" New Drug Application",
            "authors": [
                {
                    "first": "G.D.",
                    "middle": [],
                    "last": "Novack",
                    "suffix": ""
                }
            ],
            "year": 2009,
            "venue": "Ocul Surf",
            "volume": "7",
            "issn": "1",
            "pages": "53-55",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF7": {
            "title": "Pipeline: The right to try",
            "authors": [
                {
                    "first": "G.D.",
                    "middle": [],
                    "last": "Novack",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "Ocul Surf",
            "volume": "13",
            "issn": "1",
            "pages": "88-89",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF8": {
            "title": "",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF9": {
            "title": "A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19",
            "authors": [
                {
                    "first": "B.",
                    "middle": [],
                    "last": "Cao",
                    "suffix": ""
                },
                {
                    "first": "Y.",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "D.",
                    "middle": [],
                    "last": "Wen",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "N Engl J Med",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF10": {
            "title": "",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF11": {
            "title": "Betaxolol and timolol: a comparison of efficacy and side effects",
            "authors": [
                {
                    "first": "D.B.",
                    "middle": [],
                    "last": "Berry",
                    "suffix": ""
                },
                {
                    "first": "E.M.",
                    "middle": [],
                    "last": "van Buskirk",
                    "suffix": ""
                },
                {
                    "first": "M.B.",
                    "middle": [],
                    "last": "Shields",
                    "suffix": ""
                }
            ],
            "year": 1984,
            "venue": "Arch Ophthalmol",
            "volume": "",
            "issn": "",
            "pages": "10242-10245",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF12": {
            "title": "",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF13": {
            "title": "",
            "authors": [],
            "year": null,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF14": {
            "title": "A double-masked comparison of betaxolol vs timolol in the treatment of open-angle glaucoma",
            "authors": [
                {
                    "first": "R.C.",
                    "middle": [],
                    "last": "Allen",
                    "suffix": ""
                },
                {
                    "first": "E.",
                    "middle": [],
                    "last": "Hertzmark",
                    "suffix": ""
                },
                {
                    "first": "A.M.",
                    "middle": [],
                    "last": "Walker",
                    "suffix": ""
                },
                {
                    "first": "D.L.",
                    "middle": [],
                    "last": "Epstein",
                    "suffix": ""
                }
            ],
            "year": 1986,
            "venue": "Am J Ophthalmol",
            "volume": "",
            "issn": "",
            "pages": "101535-101541",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF15": {
            "title": "How many vs. how much",
            "authors": [
                {
                    "first": "G.D.",
                    "middle": [],
                    "last": "Novack",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "Ocul Surf",
            "volume": "17",
            "issn": "1",
            "pages": "167-171",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF16": {
            "title": "Pipeline: Some are more equal than others",
            "authors": [
                {
                    "first": "G.D.",
                    "middle": [],
                    "last": "Novack",
                    "suffix": ""
                }
            ],
            "year": 2014,
            "venue": "Ocul Surf",
            "volume": "12",
            "issn": "2",
            "pages": "155-158",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF17": {
            "title": "Two Phase 3 Clinical Trials Comparing the Safety and Efficacy of Netarsudil to Timolol in Patients With Elevated Intraocular Pressure: Rho Kinase Elevated IOP Treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2)",
            "authors": [
                {
                    "first": "J.B.",
                    "middle": [],
                    "last": "Serle",
                    "suffix": ""
                },
                {
                    "first": "L.J.",
                    "middle": [],
                    "last": "Katz",
                    "suffix": ""
                },
                {
                    "first": "E.",
                    "middle": [],
                    "last": "McLaurin",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Am J Ophthalmol",
            "volume": "",
            "issn": "",
            "pages": "186116-186127",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF18": {
            "title": "An artificial tear containing flaxseed oil for treating dry eye disease: A randomized controlled trial",
            "authors": [
                {
                    "first": "L.E.",
                    "middle": [],
                    "last": "Downie",
                    "suffix": ""
                },
                {
                    "first": "M.M.",
                    "middle": [],
                    "last": "Hom",
                    "suffix": ""
                },
                {
                    "first": "G.J.",
                    "middle": [],
                    "last": "Berdy",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Ocul Surf",
            "volume": "18",
            "issn": "1",
            "pages": "148-157",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF19": {
            "title": "TFOS DEWS II Clinical Trial Design Report",
            "authors": [
                {
                    "first": "G.D.",
                    "middle": [],
                    "last": "Novack",
                    "suffix": ""
                },
                {
                    "first": "P.",
                    "middle": [],
                    "last": "Asbell",
                    "suffix": ""
                },
                {
                    "first": "S.",
                    "middle": [],
                    "last": "Barabino",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "Ocul Surf",
            "volume": "15",
            "issn": "3",
            "pages": "629-649",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF20": {
            "title": "Emixustat Reduces Metabolic Demand of Dark Activity in the Retina",
            "authors": [
                {
                    "first": "R.",
                    "middle": [],
                    "last": "Kubota",
                    "suffix": ""
                },
                {
                    "first": "D.J.",
                    "middle": [],
                    "last": "Calkins",
                    "suffix": ""
                },
                {
                    "first": "S.H.",
                    "middle": [],
                    "last": "Henry",
                    "suffix": ""
                },
                {
                    "first": "R.A.",
                    "middle": [],
                    "last": "Linsenmeier",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "Investigative Ophthalmology & Visual Science",
            "volume": "60",
            "issn": "14",
            "pages": "4924-4930",
            "other_ids": {
                "DOI": []
            }
        }
    }
}